NovaBridge Biosciences Capitalized Contract Cost, Impairment Loss
NovaBridge Biosciences (NBP) reported Capitalized Contract Cost, Impairment Loss of CNY 0 for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostImpairmentLoss · last filed 2024-04-30
| Period end | Capitalized Contract Cost, Impairment Loss 6 month | Capitalized Contract Cost, Impairment Loss 12 month |
|---|---|---|
| 2023-12-31 | 0.00 CNY 20-F · filed 2024-04-30 | |
| 2022-12-31 | 0.00 CNY 20-F · filed 2024-04-30 | |
| 2022-06-30 | 0.00 CNY 6-K · filed 2022-11-10 | |
| 2021-12-31 | 0.00 CNY 20-F · filed 2024-04-30 | |
| 2020-12-31 | 0.00 CNY 20-F · filed 2023-05-01 | |
| 2019-12-31 | 0.00 CNY 20-F · filed 2022-04-29 |